HATFIELD, England, May 15, 2014 /PRNewswire/ --
FOR EMEA MEDIA ONLY - NOT FOR SWISS JOURNALISTS
Data underscore breadth of oncology portfolio
Eisai announced today that 16 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from 30 May to 3 June, 2014.
"Anchored by our human health care mission, Eisai's commitment to people with cancer and their families is evidenced by our focus on sometimes overlooked patient populations, and our investment in the development of innovative treatment options that have the potential to impact these communities. Oncology is a key franchise area for our company with a diverse portfolio of treatments and supportive care agents. The studies being presented at this year's ASCO Annual Meeting reflect our hhc mission and commitment to providing options for people with cancer in need, whether those needs affect a few or many," said Kenichi Nomoto, Ph.D., President, Oncology Product Creation Unit at Eisai Inc.
Of note, the results of a Phase III study with lenvatinib, an investigational agent being evaluated for the treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC), will be included in the ASCO press conference on Saturday 31 May. The data will also be presented on Monday 2 June, 2014.
Additional presentations will include results from the continued study of Halaven® (eribulin) for investigational uses in both early and late-stage breast cancer.
The following Eisai abstracts are accepted for presentation at this year's ASCO meeting:
Product Abstract Name Lenvatinib A phase III, multicenter, double-blind, (E7080) placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid Abstract No: cancer (SELECT). LBA6008 Oral Presentation Lenvatinib Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of (E7080) approximately 500 patients treated with lenvatinib across tumor types. Abstract No: 11061 Poster Presentation Lenvatinib A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus (E7080) sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. Abstract No: TPS4153 Poster Presentation Lenvatinib E7080 (Lenvatinib) in Addition to Best Supportive Care (BSC) versus BSC Alone in Third Line or Greater (E7080) Non-Squamous, Non Small Cell Lung Cancer (NSCLC) Abstract No: 8043 Poster Presentation Pharmokinetics (PK) of eribulin mesylate in cancer Eribulin patients with normal and impaired renal function. Abstract No: 2595 Poster Presentation Efficacy of eribulin in patients with metastatic breast Eribulin cancer (MBC): a pooled analysis by HER2 and ER status. Abstract No: 631 Poster Presentation Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): results Eribulin from 2 Phase 2, multicenter, single-arm studies. Abstract No: 629 Poster Presentation Clinical effects of prior trastuzumab on combination eribulin mesylate + trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): results from a phase 2, single-arm, multicenter Eribulin study. Abstract No: 635 Poster Presentation Phase II feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate Eribulin with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC) Abstract No: TPS670 Poster Presentation Eribulin Phase I/IB trial of eribulin and everolimus in patients with triple negative metastatic breast cancer (TNBC) Abstract No: TPS2637 Poster Presentation Phase I/II trial of eribulin mesylate carboplatin and trastuzumab (ECH) as neoadjuvant therapy for operable Eribulin HER2 positive (HER2+) breast cancer Abstract No: 604 Poster Presentation A Phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with Eribulin metastatic, human epidermal growth factor receptor 2-positive breast cancer Abstract No: TPS668 Poster Presentation Eribulin Phase II study of eribulin mesylate in patients with Abstract No: advanced soft tissue sarcoma 10567 Poster Presentation Time to progression and time to treatment failure in patients with triple-negative metastatic breast cancer Eribulin receiving eribulin mesylate in a community oncology setting Abstract No: E12039 Publication Only A Comparative Effectiveness Analysis of Single Agent Eribulin Cytotoxics in Triple Negative Metastatic Breast Cancer (TN-MBC) Patients Abstract No: E17648 Publication Only Efficacy and toxicity profile of eribulin mesylate for Eribulin metastatic breast cancer (MBC) patients (pts) in the routine clinic: A French observational study Abstract No: E11555 Publication Only
Some of the information discussed in this release is about investigational uses for eribulin and an investigational product lenvatinib. Eribulin is indicated in Europe for the treatment of patients with locally advanced or MBC who have previously received at least two chemotherapeutic regimens. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.
Notes to Editors
Eisai in Oncology
Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications.
Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the treatment of people with breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease and whose prior therapy should have included an anthracycline and a taxane. Eribulin belongs to a class of antineoplastic agents, the halichondrins, which are natural products, isolated from the marine sponge Halichondria okadai. It is believed to work by inhibiting the growth phase of microtubule dynamics which prevents cell division.
Lenvatinib is an orally active, selective inhibitor of receptor tyrosine kinases (RTKs), including KDR (VEGFR-2), Flt-1 (VEGFR-1), FGFR1, PDGFR-β and c-kit involved in angiogenesis and tumour proliferation., It is currently under investigation as a treatment for thyroid, hepatocellular, endometrial and other solid tumour types. Eisai has initiated a global phase III trial with lenvatinib in hepatocellular carcinoma (HCC) and is conducting phase II studies of lenvatinib in several other tumour types.
Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc.
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium, Luxembourg, Russia and the Middle East.
For further information please visit our web site http://www.eisai.co.uk
1. SPC Halaven (updated December 2013). Available at: http://www.medicines.org.uk/emc/medicine/24382. Last accessed May 2014
2. Matsui J, et al. Clin Cancer Res 2008;14:5459-65
3. Matsui J, et al. Int J Cancer 2008;122:664-71
Date of preparation: May 2014
Job code: Oncology-UK0015h
SOURCE Eisai Europe Limited